An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

Mycobacterium tuberculosis (M. tb) has led to approximately 1.3 million deaths globally in
2020 according to the World Health Organization (WHO). More effective treatments are …

An effective protein-based vaccine for tuberculosis will require a safe and effective adjuvant.
There are few adjuvants in approved human vaccines, including alum and the oil-in-water …

Background Previously we have shown that Ag85B-TB10. 4 is a highly efficient vaccine
against tuberculosis when delivered in a Th1 inducing adjuvant based on cationic …

Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing
family, which has been tested in small animal models in order to study its virulence and its …

One third of the world is infected with Mycobacterium tuberculosis (Mtb) with eight million
new cases of active tuberculosis (TB) each year. Development of a new vaccine to augment …

Background. Recent advances in rational adjuvant design and antigen selection have
enabled a new generation of vaccines with potential to treat and prevent infectious disease …

Background In the search for more potent and safer tuberculosis vaccines, CAF01 was
identified as a remarkable formulation. Based on cationic liposomes and including a …

It is estimated that one third of the world's population is infected with Mycobacterium
tuberculosis (Mtb). This astounding statistic, in combination with costly and lengthy treatment …

Tuberculosis is a major health concern. Non-living tuberculosis (TB) vaccine candidates
may not only be safer than the current vaccine (BCG) but could also be used to boost BCG to …